Verrica Pharmaceuticals Inc

Verrica has secured a credit facility of up to $27.5 million from a company controlled by chairman and major shareholder Paul B. Manning. Up to $12.5 million is available immediately, with a further $15 million to be released upon achievement of certain revenue, growth and operational milestones. The funds are intended to support commercialization of YCANTH, a global phase‑3 program for common warts, and general corporate purposes; the financing is secured by assets, bears interest at SOFR plus 8.00% (SOFR floor 4.50%), with interest payable in kind and a maturity date of December 31, 2030, and involves no issuance of warrants. » More on de.investing.com

Verrica Pharmaceuticals reported revenue of $5.0 million in Q1 2026, an increase of 25.4% year over year, with YCANTH contributing $4.3 million (86% of revenue) in the U.S. Gross margin remained stable at 87.3%, while the GAAP net loss narrowed to $9.7 million ($0.45 per share). The company expects Q2 2026 EPS of -$0.50 and revenue of $6 million, but sees a cash runway only through Q1 2027 and potential financing needs. Despite the results, the stock fell 3.38% in after-hours trading. » More on de.investing.com

Verrica Pharmaceuticals released figures for the quarter ended 31 Dec 2025: EPS was -$0.57 versus -$2.40 in the prior-year quarter. Quarterly revenue rose 1,397.06% to $5.1 million. For the fiscal year, the company reported EPS of -$1.68 (prior year -$14.80) and annual revenue of $35.58 million, an increase of 370.01% versus the prior year. » More on finanzen.net